Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Navoximod - Lumos Pharma/Genentech

Next Previous
X
Search
Drug Profile

Navoximod - Lumos Pharma/Genentech

Alternative Names: GDC-0919; NLG-919; RG-6078

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lankenau Institute for Medical Research
  • Developer Chugai Pharmaceutical; Genentech; Lumos Pharma
  • Class Antineoplastics; Cyclohexanes; Imidazoles; Indoles; Small molecules
  • Mechanism of Action Immunomodulators; Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 30 Sep 2022 Lumos Pharma withdraws a phase I trial for Solid tumours (Late-stage disease, Combination therapy, Second-line therapy or greater, In adolescents, In adults, In elderly) in the US, prior to enrollment due to lack of funding support (NCT05469490)
  • 26 Jul 2022 Lumos Pharma plans a phase I trial for Solid tumours (Late-stage disease, Combination therapy, Second-line therapy or greater, In adolescents, In adults, In elderly) in the US (NCT05469490)
  • 28 Oct 2021 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in France (PO, Capsule)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top